BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 193.00
+1.50 (0.78%)
Jul 21, 2026, 4:08 PM HKT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 |
BRUKINSA Revenue | 4.23B | 3.93B | 2.64B | |||||||||||
BRUKINSA Revenue Growth | 7.72% | 48.57% | 104.92% | |||||||||||
TEVIMBRA Revenue | 772.38M | 737.30M | 620.84M | |||||||||||
TEVIMBRA Revenue Growth | 4.76% | 18.76% | 15.69% | |||||||||||
XGEVA Revenue | 325.48M | 305.98M | 224.40M | |||||||||||
XGEVA Revenue Growth | 6.37% | 36.35% | 141.74% | |||||||||||
BLINCYTO Revenue | 114.35M | 104.22M | 74.33M | |||||||||||
BLINCYTO Revenue Growth | 9.72% | 40.22% | 36.78% | |||||||||||
KYPROLIS Revenue | 72.22M | 74.97M | 66.17M | |||||||||||
KYPROLIS Revenue Growth | -3.68% | 13.30% | 66.26% | |||||||||||
POBEVCY Revenue | 45.78M | 47.40M | 53.51M | |||||||||||
POBEVCY Revenue Growth | -3.41% | -11.42% | -5.37% | |||||||||||
REVLIMID Revenue | - | - | 36.03M | |||||||||||
REVLIMID Revenue Growth | - | - | -52.61% | |||||||||||
Other Product Revenue | - | - | 60.04M | |||||||||||
Other Product Revenue Growth | - | - | 38.66% | |||||||||||
Total Other Product Revenue | 98.98M | 83.69M | 96.07M | |||||||||||
Total Other Product Revenue Growth | 18.27% | -12.88% | -19.48% | |||||||||||
Total Product Revenue | 5.66B | 5.28B | 3.78B | |||||||||||
Total Product Revenue Growth | 7.17% | 39.75% | 72.59% | |||||||||||
Collaboration Revenue | 78.33M | 60.97M | 30.70M | |||||||||||
Collaboration Revenue Growth | 28.47% | 98.64% | -88.59% | |||||||||||
Revenue (Total) | 5.67B | 5.34B | 3.81B | |||||||||||
Revenue (Total) Growth | 6.20% | 40.23% | 54.96% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 |
U.S. Revenue | 3.10B | 2.88B | 1.96B | |||||||||||
U.S. Revenue Growth | 7.47% | 47.14% | 73.50% | |||||||||||
China Revenue | 1.75B | 1.68B | 1.41B | |||||||||||
China Revenue Growth | 4.31% | 19.00% | 28.07% | |||||||||||
Europe Revenue | 686.81M | 611.37M | 362.63M | |||||||||||
Europe Revenue Growth | 12.34% | 68.59% | 79.51% | |||||||||||
Rest of World Revenue | 205.10M | 171.81M | 78.81M | |||||||||||
Rest of World Revenue Growth | 19.38% | 118.00% | 196.33% | |||||||||||
Rest of World Revenue (Pre-Q3 2022 Reporting) | 891.91M | 783.18M | 441.44M | |||||||||||
Rest of World Revenue (Pre-Q3 2022 Reporting) Growth | 13.88% | 77.42% | 93.10% | |||||||||||
Revenue (Other) | -65.11M | 2.00K | -6.00K | |||||||||||
Revenue (Total) | 5.67B | 5.34B | 3.81B | |||||||||||
Revenue (Total) Growth | 6.20% | 40.23% | 54.96% |